Plain-English translation of NCT07235930 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a combination of four medications—including serplulimab and bevacizumab added to two types of chemotherapy—can help people with advanced pancreatic cancer live longer than chemotherapy alone. About 292 patients will be randomly assigned to receive either the new four-drug combination or standard chemotherapy, and researchers will track how well the treatment works and how safe it is.
Pancreatic cancer is very difficult to treat, and current standard chemotherapy has limited effectiveness. This trial aims to see if adding newer immunotherapy medications to standard chemotherapy can improve survival and give patients better outcomes.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new four-drug combination or standard chemotherapy. Treatment involves multiple rounds of intravenous medications given over several weeks, with regular visits to the hospital or clinic for treatment and blood tests. You would continue treatment until your cancer stops responding, you experience unacceptable side effects, or the study ends—which could last many months. Throughout the trial, you'll have imaging scans and lab work to monitor how well the treatment is working and how your body is tolerating it.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China